4/10/2009 6:51:48 AM
ScienceDaily (Apr. 10, 2009) — In a new study, a therapeutic agent called sorafenib dramatically improved the condition of rats with portal hypertension. The drug is already approved in several countries for treatment of kidney and liver cancer, and it may be time to consider it for patients suffering from advanced portal hypertension, the authors suggest.
comments powered by